Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 363

1.

Identification of Plasma Inositol and Indoxyl Sulfate as Novel Biomarker Candidates for Atherosclerosis in Patients with Type 2 Diabetes. -Findings from Metabolome Analysis Using GC/MS.

Omori K, Katakami N, Arakawa S, Yamamoto Y, Ninomiya H, Takahara M, Matsuoka TA, Tsugawa H, Furuno M, Bamba T, Fukusaki E, Shimomura I.

J Atheroscler Thromb. 2020 Jan 25. doi: 10.5551/jat.52506. [Epub ahead of print]

2.

Proposal of predictive model on survival in unresectable pancreatic cancer receiving systemic chemotherapy.

Ishii N, Nishikawa H, Iwata Y, Enomoto H, Tanaka H, Katakami N, Nishimura T, Iijima H, Nishiguchi S.

J Cancer. 2020 Jan 1;11(5):1223-1230. doi: 10.7150/jca.38861. eCollection 2020.

3.

Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double-positive lung cancer.

Takeuchi S, Hase T, Shimizu S, Ando M, Hata A, Murakami H, Kawakami T, Nagase K, Yoshimura K, Fujiwara T, Tanimoto A, Nishiyama A, Arai S, Fukuda K, Katakami N, Takahashi T, Hasegawa Y, Ko TK, Ong ST, Yano S.

Cancer Sci. 2020 Feb;111(2):561-570. doi: 10.1111/cas.14260. Epub 2020 Jan 6.

4.

A multi-center, Phase II trial of nab-paclitaxel and gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

Tachihara M, Kiriu T, Hata A, Hatakeyama Y, Nakata K, Nagano T, Yamamoto M, Kobayashi K, Ohnishi H, Katakami N, Nishimura Y.

Cancer Manag Res. 2019 Jul 29;11:7135-7140. doi: 10.2147/CMAR.S208224. eCollection 2019.

5.

Predictive factors of posttransplant glucose intolerance in Japanese patients with type 1 diabetes after pancreas transplantation.

Takahi Y, Miyashita K, Takahara M, Katakami N, Kuroda A, Matsuoka TA, Matsuhisa M, Ito T, Shimomura I.

Endocr J. 2019 Dec 25;66(12):1101-1112. doi: 10.1507/endocrj.EJ19-0180. Epub 2019 Sep 7.

6.

Consistency of plasma glucagon levels in patients with type 1 diabetes after a 1-year period.

Kawamori D, Katakami N, Takahara M, Miyashita K, Takebe S, Yasuda T, Matsuoka TA, Shimomura I.

J Diabetes Investig. 2019 Aug 29. doi: 10.1111/jdi.13134. [Epub ahead of print]

7.

Three-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: Pooled analysis of ONO-4538-05 and ONO-4538-06 studies.

Horinouchi H, Nishio M, Hida T, Nakagawa K, Sakai H, Nogami N, Atagi S, Takahashi T, Saka H, Takenoyama M, Katakami N, Tanaka H, Takeda K, Satouchi M, Isobe H, Maemondo M, Goto K, Hirashima T, Minato K, Sumiyoshi N, Tamura T.

Cancer Med. 2019 Sep;8(11):5183-5193. doi: 10.1002/cam4.2411. Epub 2019 Jul 29.

8.

Protocol of a Prospective Observational Study on the Relationship Between Glucose Fluctuation and Cardiovascular Events in Patients with Type 2 Diabetes.

Mita T, Katakami N, Okada Y, Yoshii H, Osonoi T, Nishida K, Shiraiwa T, Torimoto K, Kurozumi A, Wakasugi S, Gosho M, Shimomura I, Watada H.

Diabetes Ther. 2019 Oct;10(5):1565-1575. doi: 10.1007/s13300-019-0665-8. Epub 2019 Jul 23.

9.

Phase I/II Study of Osimertinib With Bevacizumab in EGFR-mutated, T790M-positive Patients With Progressed EGFR-TKIs: West Japan Oncology Group 8715L (WJOG8715L).

Akamatsu H, Teraoka S, Morita S, Katakami N, Tachihara M, Daga H, Yamamoto N, Nakagawa K.

Clin Lung Cancer. 2019 Jul;20(4):e492-e494. doi: 10.1016/j.cllc.2019.03.002. Epub 2019 Mar 19.

10.

Development of an LC-MS/MS-based method for quantitation of osimertinib in human plasma and cerebrospinal fluid.

Irie K, Nanjo S, Hata A, Yamasaki Y, Okada Y, Katakami N, Fukushima S.

Bioanalysis. 2019 May;11(9):847-854. doi: 10.4155/bio-2018-0292. Epub 2019 May 14.

PMID:
31084202
11.

Circulating osteocalcin as a bone-derived hormone is inversely correlated with body fat in patients with type 1 diabetes.

Takashi Y, Ishizu M, Mori H, Miyashita K, Sakamoto F, Katakami N, Matsuoka TA, Yasuda T, Hashida S, Matsuhisa M, Kuroda A.

PLoS One. 2019 May 3;14(5):e0216416. doi: 10.1371/journal.pone.0216416. eCollection 2019.

12.

Clinical utility of carotid ultrasonography: Application for the management of patients with diabetes.

Katakami N, Matsuoka TA, Shimomura I.

J Diabetes Investig. 2019 Jul;10(4):883-898. doi: 10.1111/jdi.13042. Epub 2019 Apr 15. Review.

13.

Prospective analysis of the association between skeletal-related events and quality of life in patients with advanced lung cancer (CSP-HOR13).

Kunikane H, Yokota I, Katakami N, Takeda K, Takayama K, Sawa T, Saito H, Harada M, Yokota S, Ando K, Saito Y, Ohashi Y, Eguchi K.

Oncol Lett. 2019 Jan;17(1):1320-1326. doi: 10.3892/ol.2018.9680. Epub 2018 Nov 9.

14.

Salvage Pulmonary Operations Following Stereotactic Body Radiotherapy for Small Primary and Metastatic Lung Tumors: Evaluation of the Operative Procedures.

Hamakawa H, Takahashi Y, Sakanoue I, Saito T, Date N, Tomii K, Katakami N, Imagunbai T, Kokubo M.

Technol Cancer Res Treat. 2018 Jan 1;17:1533033818807431. doi: 10.1177/1533033818807431.

15.

Does afatinib plus bevacizumab combination therapy induce positive conversion of T790M in previously-negative patients?

Hata A, Katakami N, Kaji R, Yokoyama T, Kaneda T, Tamiya M, Inoue T, Kimura H, Yano Y, Tamura D, Morita S, Negoro S; HANSHIN Oncology Group.

Oncotarget. 2018 Oct 5;9(78):34765-34771. doi: 10.18632/oncotarget.26192. eCollection 2018 Oct 5.

16.

Evaluation of health utility values for diabetic complications, treatment regimens, glycemic control and other subjective symptoms in diabetic patients using the EQ-5D-5L.

Takahara M, Katakami N, Shiraiwa T, Abe K, Ayame H, Ishimaru Y, Iwamoto M, Shimizu M, Tomonaga O, Yokoyama H, Matsuoka TA, Shimomura I.

Acta Diabetol. 2019 Mar;56(3):309-319. doi: 10.1007/s00592-018-1244-6. Epub 2018 Oct 23.

PMID:
30353354
17.

Different daily glycemic profiles after switching from once-daily alogliptin plus twice-daily metformin to their once-daily fixed-dose combination in Japanese type 2 diabetic patients.

Takahara M, Shiraiwa T, Katakami N, Maeno Y, Yamamoto K, Shiraiwa Y, Yoshida Y, Matsuoka TA, Shimomura I.

Endocr J. 2019 Jan 28;66(1):11-17. doi: 10.1507/endocrj.EJ18-0313. Epub 2018 Oct 11.

18.

Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316).

Tachihara M, Negoro S, Inoue T, Tamiya M, Akazawa Y, Uenami T, Urata Y, Hattori Y, Hata A, Katakami N, Yokota S.

BMC Cancer. 2018 Oct 3;18(1):946. doi: 10.1186/s12885-018-4819-2.

19.

Team Management of Skin Rash Associated with Use of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors.

Masago K, Imamichi F, Masuda Y, Ariga N, Fujitomi K, Fukumine Y, Hatakenaka K, Fujita S, Katakami N.

Asia Pac J Oncol Nurs. 2018 Oct-Dec;5(4):430-434. doi: 10.4103/apjon.apjon_33_18.

20.

Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutations.

Uchibori K, Satouchi M, Sueoka-Aragane N, Urata Y, Sato A, Imamura F, Inoue T, Tachihara M, Kobayashi K, Katakami N, Kokan C, Hirashima T, Iwanaga K, Mori M, Aoe K, Morita S, Negoro S.

Lung Cancer. 2018 Oct;124:65-70. doi: 10.1016/j.lungcan.2018.07.031. Epub 2018 Jul 23.

PMID:
30268482
21.
22.

Osimertinib With Ramucirumab in EGFR-mutated, T790M-positive Patients With Progression During EGFR-TKI Therapy: Phase Ib Study.

Akamatsu H, Koh Y, Ozawa Y, Fujimoto D, Hata A, Katakami N, Tomii K, Shimokawa T, Yamamoto N.

Clin Lung Cancer. 2018 Nov;19(6):e871-e874. doi: 10.1016/j.cllc.2018.08.001. Epub 2018 Aug 22.

23.

Afatinib plus bevacizumab combination after acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: Multicenter, single-arm, phase 2 trial (ABC Study).

Hata A, Katakami N, Kaji R, Yokoyama T, Kaneda T, Tamiya M, Inoue T, Kimura H, Yano Y, Tamura D, Morita S, Negoro S, The Hanshin Oncology Group F.

Cancer. 2018 Oct 1;124(19):3830-3838. doi: 10.1002/cncr.31678. Epub 2018 Sep 7.

24.

Skin autofluorescence is associated with vascular complications in patients with type 2 diabetes.

Osawa S, Katakami N, Sato I, Ninomiya H, Omori K, Yamamoto Y, Takahara M, Miyashita K, Sakamoto F, Kawamori D, Matsuoka T, Shimomura I.

J Diabetes Complications. 2018 Sep;32(9):839-844. doi: 10.1016/j.jdiacomp.2018.06.009. Epub 2018 Jun 22.

PMID:
30099985
25.

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC.

Arasada RR, Shilo K, Yamada T, Zhang J, Yano S, Ghanem R, Wang W, Takeuchi S, Fukuda K, Katakami N, Tomii K, Ogushi F, Nishioka Y, Talabere T, Misra S, Duan W, Fadda P, Rahman MA, Nana-Sinkam P, Evans J, Amann J, Tchekneva EE, Dikov MM, Carbone DP.

Nat Commun. 2018 Aug 10;9(1):3198. doi: 10.1038/s41467-018-05626-2.

26.

Identification of Metabolites Associated with Onset of CAD in Diabetic Patients Using CE-MS Analysis: A Pilot Study.

Omori K, Katakami N, Yamamoto Y, Ninomiya H, Takahara M, Matsuoka TA, Bamba T, Fukusaki E, Shimomura I.

J Atheroscler Thromb. 2019 Mar 1;26(3):233-245. doi: 10.5551/jat.42945. Epub 2018 Aug 1.

27.

CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3).

Wu YL, Ahn MJ, Garassino MC, Han JY, Katakami N, Kim HR, Hodge R, Kaur P, Brown AP, Ghiorghiu D, Papadimitrakopoulou VA, Mok TSK.

J Clin Oncol. 2018 Sep 10;36(26):2702-2709. doi: 10.1200/JCO.2018.77.9363. Epub 2018 Jul 30.

PMID:
30059262
28.

An LC-MS/MS Method for Absolute Quantification of Nivolumab in Human Plasma: Application to Clinical Therapeutic Drug Monitoring.

Irie K, Okada A, Yamasaki Y, Kokan C, Hata A, Kaji R, Fukushima K, Sugioka N, Okada Y, Katakami N, Fukushima S.

Ther Drug Monit. 2018 Dec;40(6):716-724. doi: 10.1097/FTD.0000000000000558.

PMID:
30048380
29.

Maintenance ramucirumab monotherapy after intolerable toxicities following docetaxel plus ramucirumab.

Hata A, Katakami N.

Oncotarget. 2018 Jun 19;9(47):28292-28293. doi: 10.18632/oncotarget.25623. eCollection 2018 Jun 19. No abstract available.

30.

Docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte-colony stimulating factor for pretreated non-small cell lung cancer.

Hata A, Harada D, Okuda C, Kaji R, Masuda Y, Takechi Y, Kozuki T, Nogami N, Katakami N.

Oncotarget. 2018 Jun 12;9(45):27789-27796. doi: 10.18632/oncotarget.25578. eCollection 2018 Jun 12.

31.

Association between Subclinical Atherosclerosis Markers and the Level of Accumulated Advanced Glycation End-Products in the Skin of Patients with Diabetes.

Ninomiya H, Katakami N, Sato I, Osawa S, Yamamoto Y, Takahara M, Kawamori D, Matsuoka TA, Shimomura I.

J Atheroscler Thromb. 2018 Dec 1;25(12):1274-1284. doi: 10.5551/jat.44859. Epub 2018 Jun 30.

32.

Relationship between Paronychia and Drug Concentrations of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.

Masago K, Irie K, Fujita S, Imamichi F, Okada Y, Katakami N, Fukushima S, Yatabe Y.

Oncology. 2018;95(4):251-256. doi: 10.1159/000490177. Epub 2018 Jun 14.

PMID:
29902802
33.

Dysregulated plasma glucagon levels in Japanese young adult type 1 diabetes patients.

Kawamori D, Katakami N, Takahara M, Miyashita K, Sakamoto F, Yasuda T, Matsuoka TA, Shimomura I.

J Diabetes Investig. 2019 Jan;10(1):62-66. doi: 10.1111/jdi.12862. Epub 2018 Jun 7.

34.

Sleeve lobectomy for lung adenocarcinoma treated with neoadjuvant afatinib.

Sakanoue I, Hamakawa H, Kaji R, Imai Y, Katakami N, Takahashi Y.

J Thorac Dis. 2018 Mar;10(3):E170-E174. doi: 10.21037/jtd.2018.02.03.

35.

Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial.

Akamatsu H, Katakami N, Okamoto I, Kato T, Kim YH, Imamura F, Shinkai M, Hodge RA, Uchida H, Hida T.

Cancer Sci. 2018 Jun;109(6):1930-1938. doi: 10.1111/cas.13623. Epub 2018 May 31.

36.

Development and validation of a method for gefitinib quantification in dried blood spots using liquid chromatography-tandem mass spectrometry: Application to finger-prick clinical blood samples of patients with non-small cell lung cancer.

Irie K, Shobu S, Hiratsuji S, Yamasaki Y, Nanjo S, Kokan C, Hata A, Kaji R, Masago K, Fujita S, Okada Y, Katakami N, Fukushima S.

J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Jun 15;1087-1088:1-5. doi: 10.1016/j.jchromb.2018.04.027. Epub 2018 Apr 13.

PMID:
29689441
37.

Assessment of exposure risk of irinotecan and its active metabolite, SN-38, through perspiration during chemotherapy.

Irie K, Okada A, Masuda Y, Fukushima K, Sugioka N, Okuda C, Hata A, Kaji R, Okada Y, Katakami N, Fukushima S.

J Oncol Pharm Pract. 2019 Jun;25(4):865-868. doi: 10.1177/1078155218769136. Epub 2018 Apr 13.

PMID:
29651916
38.

Incomplete Systematic Meta-analysis of Pharmacological Therapies for Opioid-Induced Constipation.

Katakami N.

J Pain Symptom Manage. 2018 Jun;55(6):e3. doi: 10.1016/j.jpainsymman.2018.03.003. Epub 2018 Mar 13. No abstract available.

PMID:
29545066
39.
40.

Clinical Utility of Carotid Ultrasonography in the Prediction of Cardiovascular Events in Patients with Diabetes: A Combined Analysis of Data Obtained in Five Longitudinal Studies.

Katakami N, Mita T, Gosho M, Takahara M, Irie Y, Yasuda T, Matsuoka TA, Osonoi T, Watada H, Shimomura I.

J Atheroscler Thromb. 2018 Oct 1;25(10):1053-1066. doi: 10.5551/jat.43141. Epub 2018 Feb 14.

41.

Computed tomography-guided lung biopsy: Association between biopsy needle angle and pneumothorax development.

Kuriyama T, Masago K, Okada Y, Katakami N.

Mol Clin Oncol. 2018 Feb;8(2):336-341. doi: 10.3892/mco.2017.1512. Epub 2017 Nov 27.

42.

Quantitative Analysis of Conebeam CT for Delineating Stents in Stent-Assisted Coil Embolization.

Kuriyama T, Sakai N, Beppu M, Sakai C, Imamura H, Masago K, Katakami N, Isoda H.

AJNR Am J Neuroradiol. 2018 Mar;39(3):488-493. doi: 10.3174/ajnr.A5533. Epub 2018 Feb 1.

43.

Reply to Y. Yagi et al.

Katakami N, Yokota T, Tada Y.

J Clin Oncol. 2018 Apr 1;36(10):1050. doi: 10.1200/JCO.2017.77.0925. Epub 2018 Feb 6. No abstract available.

PMID:
29406802
44.

Effect of sitagliptin on tissue characteristics of the carotid wall in patients with type 2 diabetes: a post hoc sub-analysis of the sitagliptin preventive study of intima-media thickness evaluation (SPIKE).

Katakami N, Mita T, Irie Y, Takahara M, Matsuoka TA, Gosho M, Watada H, Shimomura I; Sitagliptin Preventive study of Intima-media thickness Evaluation (SPIKE) Collaborators.

Cardiovasc Diabetol. 2018 Feb 5;17(1):24. doi: 10.1186/s12933-018-0666-3.

45.

Programmed death-ligand 1 expression according to epidermal growth factor receptor mutation status in pretreated non-small cell lung cancer.

Hata A, Katakami N, Nanjo S, Okuda C, Kaji R, Masago K, Fujita S, Yoshida H, Zama K, Imai Y, Hirata Y.

Oncotarget. 2017 Dec 1;8(69):113807-113816. doi: 10.18632/oncotarget.22837. eCollection 2017 Dec 26.

46.

Osimertinib in patients with epidermal growth factor receptor T790M advanced non-small cell lung cancer selected using cytology samples.

Kiura K, Yoh K, Katakami N, Nogami N, Kasahara K, Takahashi T, Okamoto I, Cantarini M, Hodge R, Uchida H.

Cancer Sci. 2018 Apr;109(4):1177-1184. doi: 10.1111/cas.13511. Epub 2018 Feb 27.

47.

Validation of the digital PCR system in tyrosine kinase inhibitor-resistant EGFR mutant non-small-cell lung cancer.

Masago K, Fujita S, Hata A, Okuda C, Yoshizumi Y, Kaji R, Katakami N, Hirata Y, Yatabe Y.

Pathol Int. 2018 Mar;68(3):167-173. doi: 10.1111/pin.12630. Epub 2018 Jan 17.

PMID:
29341374
48.

Exacerbation of autoimmune hemolytic anemia induced by the first dose of programmed death-1 inhibitor pembrolizumab: a case report.

Ogawa K, Ito J, Fujimoto D, Morita M, Yoshizumi Y, Ariyoshi K, Tomii K, Katakami N.

Invest New Drugs. 2018 Jun;36(3):509-512. doi: 10.1007/s10637-018-0561-5. Epub 2018 Jan 16.

PMID:
29340837
49.

Evaluation of the Effect of Alogliptin on Tissue Characteristics of the Carotid Wall: Subanalysis of the SPEAD-A Trial.

Irie Y, Katakami N, Mita T, Takahara M, Matsuoka TA, Gosho M, Watada H, Shimomura I; Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A) Collaborators.

Diabetes Ther. 2018 Feb;9(1):317-329. doi: 10.1007/s13300-018-0367-7. Epub 2018 Jan 12.

50.

Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer.

Kaneda T, Yoshioka H, Tamiya M, Tamiya A, Hata A, Okada A, Niwa T, Shiroyama T, Kanazu M, Ishida T, Katakami N.

BMC Cancer. 2018 Jan 2;18(1):6. doi: 10.1186/s12885-017-3952-7.

Supplemental Content

Loading ...
Support Center